Novogen Limited (ADR)  

(Public, NASDAQ:NVGN)   Watch this stock  
Find more results for NVGN
0.00 (0.00%)
Jan 28 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.32 - 2.47
52 week 1.51 - 5.97
Open 2.37
Vol / Avg. 133,045.00/1.27M
Mkt cap 22.32M
P/E     -
Div/yield     -
EPS -0.94
Shares 168.56M
Beta 0.75
Inst. own 0%
Feb 9, 2015
Novogen Ltd at Biotechnology Industry Organization CEO & Investor Conference - 9:00AM EST - Add to calendar
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2014
Net profit margin -7785.26% -8700.00%
Operating margin -7785.27% -8700.00%
EBITD margin - -6600.00%
Return on average assets -132.92% -145.43%
Return on average equity -279.01% -269.02%
Employees 12 -
CDP Score - -


L 1 16-20 Edgeworth David Ave
+61-2-94760344 (Phone)
+61-2-94760388 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Novogen Limited is engaged in pharmaceutical research and development, and marketing of consumer healthcare products. The Company has three segments: Drug Development, Oncology Drug Program, Consumer Business and Wound Healing. Drug Development includes the discovery of new compounds and the early stage screening for bioactivity of such compounds through both in vivo and in vitro testing. Oncology Drug Program involves the development of selected oncology drug candidates, which have indicated bioactivity against cancer cells through clinical trial programs to assess safety and efficacy. Wound Healing is a separate technology based on Beta-1 Glucan to aid in the management of wounds. The Company�s clinical development program run through Novogen�s subsidiaries Marshall Edwards, Inc. (MEI) and Glycotex, Inc. (Glycotex). In October 2013, Novogen Limited acquired a drug technology.

Officers and directors

Graham Edmund Kelly Executive Chairman of the Board, Chief Executive Officer, Managing Director
Age: 64
Bio & Compensation  - Reuters
Mark G. Hinze CPA Chief Financial Officer
Bio & Compensation  - Reuters
Daniel P. Gold Ph.D. President and Chief Executive Officer of Marshall Edwards, Inc.
Age: 60
Bio & Compensation  - Reuters
Andrew Heaton President and Chief Executive Officer of Novogen North America Inc
Bio & Compensation  - Reuters
David Brown Chief Scientific Officer
Bio & Compensation  - Reuters
Craig D. Kearney General Manager - Consumer Business
Bio & Compensation  - Reuters
Justine R. Stehn Ph.D. Director - ATM Program
Bio & Compensation  - Reuters
Thomas M. Zech Chief Financial Officer of MEI Pharma, Inc.
Age: 62
Bio & Compensation  - Reuters
Lionel Mateo Company Secretary
Bio & Compensation  - Reuters
Steven Roy Stent Coffey Non-Executive Director
Bio & Compensation  - Reuters